Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma

Summary This study aimed to investigate the survival impact of the number of lymph nodes dissection (LND) in patients receiving neoadjuvant chemotherapy (NCT) for esophageal squamous cell carcinoma (ESCC). We retrospectively analyzed the clinical pathological data and survival of 407 ESCC patients w...

Full description

Saved in:
Bibliographic Details
Published in:Diseases of the esophagus 2023-04, Vol.36 (5)
Main Authors: Jiang, Duo, Liu, Xian-Ben, Xing, Wen-Qun, Chen, Pei-Nan, Feng, Shao-Kang, Yan, Sen, Lerut, Toni, Sun, Hai-Bo
Format: Article
Language:English
Subjects:
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - surgery
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - surgery
Esophageal Squamous Cell Carcinoma - pathology
Esophageal Squamous Cell Carcinoma - surgery
Esophagectomy
Humans
Lymph Node Excision
Lymph Nodes - pathology
Lymph Nodes - surgery
Neoadjuvant Therapy
Neoplasm Staging
Prognosis
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary This study aimed to investigate the survival impact of the number of lymph nodes dissection (LND) in patients receiving neoadjuvant chemotherapy (NCT) for esophageal squamous cell carcinoma (ESCC). We retrospectively analyzed the clinical pathological data and survival of 407 ESCC patients who underwent esophagectomy after NCT between January 2015 and December 2016. The relationship between the number of LNDs and 5-year overall survival (OS) or disease-free survival (DFS) was plotted by using restricted cubic spline analysis. A Cox proportional hazards regression model was used to identify prognostic factors of OS and DFS. We observed an obvious non-linear relationship between LND and the hazard ratios (HRs) for OS (P = 0.0015) and DFS (P 
ISSN:1120-8694
1442-2050
DOI:10.1093/dote/doac082